Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »
2/191 von 416    DIMDI: MEDLINE (ME60) © NLM
ND: ME12839241
PMID: 12839241
LR: 20070221
CED: 20030703
DCO: 20031107
Autoren: Sauvé F; Paradis M; Refsal KR; Moreau M; Beauchamp G; Dupuis J
Titel: Effects of oral administration of meloxicam, carprofen, and a nutraceutical on thyroid function in dogs with osteoarthritis.
Quelle: The Canadian veterinary journal. La revue vétérinaire canadienne; VOL: 44 (6); p. 474-9 /200306/
PM: Print
SU: IM
Sprache: English
CY: Canada
JID: 0004653
ISSN: 0008-5286
CO: CNVJA
Institution: Département de sciences cliniques, Faculté de médecine vétérinaire, Université de Montréal, C.P. 5000, Saint-Hyacinthe, Québec J2S 7C6.
DT: Journal Article; Research Support, Non-U.S. Gov't
Schlagwörter
CT: ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/administration & dosage; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/adverse effects; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/*therapeutic use; AUTOANTIBODIES/blood; CARBAZOLES/administration & dosage; CARBAZOLES/adverse effects; CARBAZOLES/*therapeutic use; CHONDROITIN SULFATES/administration & dosage; CHONDROITIN SULFATES/therapeutic use; DOG DISEASES/*drug therapy; DOGS; FEMALE; GLUCOSAMINE/administration & dosage; GLUCOSAMINE/therapeutic use; LONGITUDINAL STUDIES; MALE; MANGANESE COMPOUNDS/administration & dosage; MANGANESE COMPOUNDS/therapeutic use; OSTEOARTHRITIS/drug therapy; OSTEOARTHRITIS/*veterinary; RANDOM ALLOCATION; THIAZINES/administration & dosage; THIAZINES/adverse effects; THIAZINES/*therapeutic use; THIAZOLES/administration & dosage; THIAZOLES/adverse effects; THIAZOLES/*therapeutic use; THYROID FUNCTION TESTS/veterinary; THYROID GLAND/*drug effects; THYROID GLAND/physiology; THYROTROPIN/blood; THYROXINE/blood; TREATMENT OUTCOME
CTG: APPLIKATION, ORALE; TIER; ANTIPHLOGISTIKA, NICHTSTEROIDALE/Verabreichung & Dosierung; ANTIPHLOGISTIKA, NICHTSTEROIDALE/unerwünschte Nebenwirkungen; ANTIPHLOGISTIKA, NICHTSTEROIDALE/*therapeutische Anwendung; AUTOANTIKÖRPER/Blut; CARBAZOLE/Verabreichung & Dosierung; CARBAZOLE/unerwünschte Nebenwirkungen; CARBAZOLE/*therapeutische Anwendung; CHONDROITINSULFATE/Verabreichung & Dosierung; CHONDROITINSULFATE/therapeutische Anwendung; HUNDEKRANKHEITEN/*Arzneimitteltherapie; HUNDE; WEIBLICH; GLUCOSAMIN/Verabreichung & Dosierung; GLUCOSAMIN/therapeutische Anwendung; LONGITUDINALSTUDIEN; MÄNNLICH; MANGANVERBINDUNGEN/Verabreichung & Dosierung; MANGANVERBINDUNGEN/therapeutische Anwendung; OSTEOARTHROSE/Arzneimitteltherapie; OSTEOARTHROSE/*Veterinärmedizin; RANDOMISIERUNG; THIAZINE/Verabreichung & Dosierung; THIAZINE/unerwünschte Nebenwirkungen; THIAZINE/*therapeutische Anwendung; THIAZOLE/Verabreichung & Dosierung; THIAZOLE/unerwünschte Nebenwirkungen; THIAZOLE/*therapeutische Anwendung; SCHILDDRÜSENFUNKTIONSTESTS/Veterinärmedizin; SCHILDDRÜSE/*Arzneimittelwirkungen; SCHILDDRÜSE/Physiologie; THYREOTROPIN/Blut; THYROXIN/Blut; BEHANDLUNGSERGEBNIS
TE: Anti-Inflammatory Agents, Non-Steroidal; Autoantibodies; Carbazoles; Manganese Compounds; Thiazines; Thiazoles; anti-thyroglobulin; Glucosamine/3416-24-8; carprofen/52263-47-5; meloxicam/71125-38-7; Thyroxine/7488-70-2; Thyrotropin/9002-71-5; Chondroitin Sulfates/9007-28-7
CR: 3416-24-8; 52263-47-5; 71125-38-7; 7488-70-2; 9002-71-5; 9007-28-7
AB: The purpose of this study was to evaluate the effect of the administration of meloxicam; carprofen; and a slow-acting disease modifying osteoarthritis agent, that contains chondroitin sulfate, purified glucosamine, and manganese ascorbate (CS-G-M), on thyroid function in dogs. Forty-six healthy (except for osteoarthritis) euthyroid dogs were blindly assigned to 3 treatment groups: meloxicam, carprofen, and CS-G-M. Each group received the recommended dose of the drug for 60 days. Sixteen other osteoarthritic euthyroid dogs, which received a placebo, were used as a control group to validate the study. For all groups, blood samples were collected on days 0, 30, and 60 to evaluate the serum total and free thyroxine, and endogenous thyrotropin concentrations. There were no significant differences among the treatment groups at each time or within each group over a 60-day period for all parameters. Moreover, none of these values were within the hypothyroid range. Based on the results of this study, the administration of meloxicam, carprofen, and CS-G-M did not affect canine thyroid function evaluation.
» Volltext »

» Fenster schließen »